Schering-Plough/Aveo Will Develop Novel Cancer Biologic Based On Biomarkers
Schering gains access to preclinical antibody, as well as biomarker profiling technology in deal worth up to $477.5 million
Schering gains access to preclinical antibody, as well as biomarker profiling technology in deal worth up to $477.5 million